About the Editors
Prof Adrian L Harris
Adrian Harris is the Cancer Research UK Professor of Medical Oncology at the University of Oxford and directs the Cancer Research UK Molecular Oncology Laboratories at the Weatherall Institute of Molecular Medicine (WIMM). He is a Consultant Medical Oncologist and a Professorial Fellow of St Hugh's College Oxford. He is Chairman of the CRUK Oxford Cancer Centre and joint lead of the Cancer theme of the Comprehensive Biomedical Research Centre in Oxford. He is a Senior Investigator in the National Institute of Health Research and a Fellow of the Academy of Medical Sciences. He is a 'Highly Cited Researcher 2014' ranking among the top 1% most cited for their subject field and year of publication-between 2002 and 2012.
He trained in Medicine and Biochemistry at Liverpool University, did a DPhil at Oxford University then trained at the Royal Marsden Hospital in Medical Oncology. He was appointed Professor of Clinical Oncology at Newcastle-upon-Tyne in 1982. Since 1988 he has been the Professor of Medical Oncology at Oxford University. His major laboratory interests involve the role of hypoxia in breast tumour biology, and tumour angiogenesis, the metabolic response to hypoxia, microRNAs induced by hypoxia and hypoxia-induced cell death. He has conducted many predictive and prognostic studies and early exploratory phase trials in new drug development and molecular pathology to translate laboratory findings to clinical relevance and development of new agents.
Dr Stephen Chia, (Clinical studies)
Stephen Chia is an Associate Professor of Medicine, Department of Medicine, University of British Columbia and a staff oncologist with the BC Cancer Agency (BCCA). Dr. Chia serves as Chair of the BC Breast Tumour Group and is a physician coordinator for both the breast cancer and head and neck cancer clinical trials at BCCA.
His main research interests are in translational research and in clinical research. His translational research is primarily focused on breast cancer, particularly assessment and validation of new and novel prognostic and predictive factors. His clinical research involves phase I-III clinical trials as well as population based outcomes research. He is also involved in phase I-II trials in investigational new drugs as well as in head and neck cancer.
Prof Jeff Evans, (Clinical studies)
Jeff Evans is a Group Leader (Translational Cancer Therapeutics Laboratory) at the CR-UK Beatson Institute, Glasgow, Professor of Translational Cancer Research and Director of the Institute of Cancer Sciences, University of Glasgow, and Honorary Consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre, Glasgow, and Lead of the Glasgow Experimental Cancer Medicine Centre (ECMC).
His research interests are in the pre-clinical and clinical development of novel anti-cancer agents, and his clinical interests are in Upper GI Cancers and Melanoma, and he leads the Phase I clinical trials and drug development team in Glasgow. He is a member of the NCRN Upper GI Cancer Pancreatic Cancer and Gastro-Oesophageal Cancer sub-groups, member of the ECMC - Industry Combinations Alliance Joint Steering Committee, member of CR-UK's Clinical Experts Review Panel, and former member of Cancer Research UK's New Agents Committee. He is co-editor of the clinical research section of the British Journal of Cancer.
Dr Suzanne Fuqua, (Translational Therapeutics)
Suzanne Fuqua is internationally recognized for her work on estrogen receptors in breast cancer. She was the first to discover constitutively active and hypersensitive estrogen receptor (ESR1) mutations in breast tumors, which has recently been confirmed by a number of investigators using next generation sequencing. It is estimated that approximately 20-40% of therapy-resistant metastatic breast tumors contain constitutively-active ESR1 mutations. She is thus a pioneer in this field.
Recently she also discovered that the androgen receptor (AR) was overexpressed in metastatic ER-positive tumors resistant to tamoxifen, and her preclinical studies have demonstrated that AR overexpression confers resistance to hormonal agents. Her work provided scientific rational for ongoing clinical trials of AR antagonists in ER-positive breast cancer.
Suzanne Fuqua is a translational scientist with many years' experience in molecular biology, functional genomics, precision medicine, steroid receptors, cell signaling and growth factor receptors.
Niels Halama (Translational Therapeutics)
Niels Halama is senior consultant of the Clinical Cancer Research Program for Colorectal Cancer at the Department of Medical Oncology of the National Center for Tumor Diseases (NCT). In addition he leads a multidisciplinary research team at the NCT, the Institute for Immunology and the BIOQUANT (all in Heidelberg, Germany).
His main clinical and scientific interests include abdominal tumors (e.g. colorectal, pancreatic, ovarian cancer), immunotherapy and tissue immunology. He is pioneering novel immunotherapies harnessing the innate immune system as well as developing tissue processing workflows, new fully human model systems and technologies combining whole slide image quantification with multiplex protein quantification to address key translational questions. Niels has been Principal Investigator in multiple early phase clinical trials. In addition to being a board certified medical oncologist, he also worked in software development for engineering companies. He received his medical training at the University of Heidelberg (Germany), at Baylor College (Texas, USA) and at MCO (Ohio, USA). Currently he is also a review editor at Frontiers in Immunology, invited member of the European Academy of Tumor Immunology and serves as a program committee member on international conferences as well as a reviewer for several international journals and funding agencies.
Prof Per Hall, (Epidemiology)
Per Hall is a medical oncologist by training and worked for many years at the Department of Oncology, Karolinska Hospital. He initiated and headed the Hereditary Breast Cancer Unit and later the Cancer Epidemiology Unit. Since 2000 he works full time as an epidemiologist at the Department of Medical Epidemiology and Biostatistics. He devotes his time to breast cancer research and is heading the Karma project.
He has recently launched a breast cancer prevention trial and has taken up a part time position at the Department of Oncology, South General Hospital, Stockholm. He is also heavily involved in the Breast Cancer Association Consortium in the quest for genetic determinants of breast cancer.
Prof Richard Houlston, (Genetics and Genomics)
Professor Richard Houlston's research is focussed on identifying and characterising susceptibility genes for cancer in order to understand the causes of tumour development. Furthermore, the ability to identify those at increased risk of developing cancer has direct clinical relevance, as it may assist preventative efforts as well as diagnosing and treating the disease in its early stage.
Richard Houlston graduated in Medicine from Imperial College, gaining MD, PhD and DSc degrees from the University of London. Following various medical internships and Fellowships he joined the ICR in 1994. Professor Houlston has been elected Fellow of the Royal College of Physicians and Pathologists, the Royal Society of Biology, the Academy of Medical Sciences and the Royal Society.
Prof David Wynford-Thomas, (Molecular Diagnostics)
David Wynford-Thomas qualified in Medicine and initially trained as a histopathologist. However, after gaining a PhD in experimental pathology followed by an NIH-funded post-doc in the USA, his career shifted towards basic and translational cancer research. His main focus has been the molecular basis of tumorigenesis in epithelial cells, using the thyroid as an experimental model. His laboratory was one of the first to recognise the importance of using primary human cells for this purpose, as opposed to the fibroblast-derived cell lines which were widely used at the time. Funded for over two decades by programme grants from CRUK, his work has helped to define the molecular and cellular basis for tumour initiation in epithelial cells by oncogenes such as ras and ret. An important spin-off from this work arose from studies into the role of p53 mutation in the later stages of tumour development. His laboratory was one of the first to demonstrate a previously unsuspected role for this tumour-suppressor gene in mediating cellular senescence. The guiding principle throughout his experimental work has been the importance, when manipulating candidate cancer genes, of using "the right genes in the right order in the right cells".
Prof Colin Goding, (Cellular and Molecular Biology)
Colin Goding completed a PhD in virology at the National Institute for Medical Research, London, UK. He then moved as a Post-doc to Pierre Chambon's lab in Strasbourg, France, where his interest in gene regulation developed. At the Marie Curie Research Institute he continued working on how genes are regulated, both in S. cerevisiae, as well as in melanocytes and melanoma. In 2008 he moved to the Ludwig Institute for Cancer Research, University of Oxford, UK to take up the position of Professor of Oncology where he continues to examine the role of signaling and transcription in melanoma biology. He has made a major contribution to understanding melanoma progression and developed the concept of phenotype-switching that underpins cancer cell plasticity and therapy resistance. He was elected EMBO member in 2008, and Director of the Oxford Stem Cell Institute in 2015. He is a visiting professor the University of Tsukuba, Japan.
Rebecca Shreeve (London, UK)
Chairman of the Editorial Board
Karen Vousden, London, UK
Scientific Publications Manager
Maria Hodges, London, UK
Arlene Back, Texas, USA
Tres Hendry, Glasgow, UK
Theresa King, Leicester, UK